ライフサイエンスコーパス: Fisher's exact test

1 th no history of breast carcinoma (P = .007, Fisher's exact test).

2 %) platinum-sensitive recurrences (P = .003, Fisher's exact test).

3 .0% to 10.7%) primary carcinomas (P = .0003, Fisher's exact test).

4 and without linkage evidence (P=2x10(-17) by Fisher's exact test).

5 rm and 10.2% in the placebo arm (P = .768 by Fisher's exact test).

6 from 62 untreated patients (3%) (P = 0.007, Fisher's Exact test).

7 ters in the VRP-HA-vaccinated group (P<.001, Fisher's exact test).

8 ients with B- and T-ALL subtypes (P = 0.011, Fisher's exact test).

9 480 ethnically matched controls (p = 0.014, Fisher's exact test).

10 ted with neurocognitive deficit (P < 0.0025, Fisher's exact test).

11 s showing loss of one copy of PU.1 (P=0.001, Fisher's exact test).

12 ras mutations (codons, 12 and 13) (P=0.048), Fisher's exact test).

13 sponse to TNF inhibitor therapy (P < 0.01 by Fisher's exact test).

14 etween the two clusters was UGT1A1 (P=0.002; Fisher's exact test).

15 noma and at 1p, 3p, and 17p in SCC (P <0.05, Fisher's exact test).

16 with the ganciclovir implant alone (P=.023; Fisher's exact test).

17 s ratio, 10.23; 95% CI, 1.3 to 83.3; P=0.01, Fisher's exact test).

18 recipients of CVD 1208 (brief fever) (P=.02, Fisher's exact test).

19 and STAT3 activation was observed (P =.007, Fisher's exact test).

20 ompared with others (48 vs 33%; p = 0.028 by Fisher's exact test).

21 h none of the 16 control patients (p = .007, Fisher's exact test).

22 was correlated with that of DAPK (P = 0.04, Fisher's exact test).

23 ason 4-6 tumors (11 out of 20, 55%, P=0.032, Fisher's exact test).

24 at received grafts from HBV- donors (P<0.05, Fisher's exact test).

25 ssified volunteers and patients (P = 0.0022, Fisher's exact test).

26 compared with adenocarcinoma (22%; P = 0.03; Fisher's exact test).

27 n and an advanced pathologic stage (P=0.003, Fisher's exact test).

28 rsus 0 of 126 white patients (P < 0.0001, by Fisher's exact test).

29 nd none of six in the SAAP-LR group (p <.05, Fisher's exact test).

30 fective for intense inflammation (P = 0.023, Fisher's exact test).

31 e of 11 of the unaffected patients (p=0.012, Fisher's exact test).

32 cation in their prior benign biopsy (P =.06, Fisher's exact test).

33 ith other histological cell types (P = 0.01, Fisher's exact test).

34 ciated with alveolar histology (P = <0.0001, Fisher's exact test).

35 d to controls (14.6% versus 10.6%; P = 0.02, Fisher's exact test).

36 r anti-P (odds ratio [OR] 9.6, P < 10(-8) by Fisher's exact test).

37 imals died within 3 days of surgery (P =.02, Fisher's exact test).

38 ly associated with infant mortality (P=.035, Fisher's exact test).

39 (P = 0.041 and P = 0.0385, respectively, by Fisher's exact test).

40 id not develop secondary neoplasms (P =.008; Fisher's exact test).

41 ed a mutation in the paired serum (P = 0.01, Fisher's exact test).

42 of 5 animal with non-inducible VT (P < 0.01, Fisher's exact test).

43 se in measurable disease (P=.0369, two-sided Fisher's exact test).

44 CCR5/CCR5 homozygotes (29/88, 33%; P < .001, Fisher's exact test).

45 ls to 0.12 in Alzheimer's disease (P < 0.05, Fisher's exact test).

46 de the prostate fossa and pelvis (P = .0225, Fisher's exact test).

47 .8%) and in 10 with ETS (52.6%) (P = 0.0298, Fisher's exact test).

48 8%) and in two with ETS (10.5%) (P = 0.0005, Fisher's exact test).

49 y between OA cases and controls (P = 0.03 by Fisher's exact test).

50 ompared with 22% in the PLA group (P < .001, Fisher's exact test).

51 ETS (47.4%) and none with HTS (P = 0.0015), Fisher's exact test).

52 ts (81.3%) but in none with ETS (P < 0.0001, Fisher's exact test).

53 e 91 elevated ESR patients (81%) (P<0.02, by Fisher's exact test).

54 on rates decreased from 19% to 8% (P = .005, Fisher's exact test).

55 the TNFR5-G1,3-treated animals (p < 0.01 by Fisher's exact test).

56 d in 0.7% and 0.1%, respectively (P=0.002 by Fisher's exact test).

57 as associated with SVR35 response (P = .018, Fisher's exact test).

58 sed with a central LBD (LBD+) (P = 0.0009 by Fisher's exact test).

59 ersistently low radioactivity (P < 0.0001 by Fisher's exact test).

60 ters combined (1.6% versus 4.7%, P = 0.02 by Fisher's exact test).

61 bject without (p = 3.12 x 10(-3), two-tailed Fisher's exact test).

62 h 6 of 34 of those with UC >1 year (P = .04, Fisher's exact test).

63 tly adjacent to a CSF reservoir (P < 0.0001, Fisher's exact test).

64 /=1:10 in postimmunization sera (P = 0.0008, Fisher's exact test).

65 cts with CHDs (p = 3.30 x 10(-2), two-tailed Fisher's exact test).

66 red to the non-ischemic patients (P = 0.005, Fisher's exact test).

67 s experiencing progression to PCa (P = .014, Fisher's exact test).

68 n the fellow eyes only in 3 cases (p = 0.13, Fisher's exact test).

69 cinomas were in the slow DT group (P<0.0002; Fisher's exact test).

70 fied in the same gene in controls (p = .023; Fisher's exact test).

71 cancers were in the slow DT group (P<0.0001; Fisher's exact test).

72 ive factor against alcoholism (P = 0.0038 by Fisher's exact tests).

73 Prevalence was compared using Fisher's exact test.

74 col was assessed with the use of a one-sided Fisher's exact test.

75 tested for by using either the chi(2) or the Fisher's exact test.

76 contingency table needed for calculating the Fisher's Exact Test.

77 with the small-sample method (SSM) based on Fisher's exact test.

78 ll survival in each group was compared using Fisher's exact test.

79 mpared between HbA1c <6 and > or =6.1% using Fisher's exact test.

80 t-test, Mann-Whitney U test, chi-square, or Fisher's exact test.

81 d by Student's t test, chi-square tests, and Fisher's exact test.

82 and delivery were made by student t test or Fisher's exact test.

83 d to those for 554 healthy controls by using Fisher's exact test.

84 HLA-DR allele frequencies among patients, by Fisher's exact test.

85 comparison of between-groups differences by Fisher's exact test.

86 ates were compared using Pearson's chi(2) or Fisher's exact test.

87 and genotype frequencies were compared using Fisher's exact test.

88 th wave and the second and third waves using Fisher's exact test.

89 Haplotype frequencies were compared using Fisher's exact test.

90 analysed using Chi-square test or Univariate Fisher's exact test.

91 olecular subtype ( P = .383), as assessed by Fisher's exact test.

92 Categorical data were evaluated with Fisher's exact test.

93 performed with Wilcoxon's rank sum test and Fisher's exact test.

94 e prevalence of mutations was compared using Fisher's exact test.

95 tween groups in proportions were assessed by Fisher's exact test.

96 3-month follow-up period was compared using Fisher's exact test.

97 these association tests were assessed using Fisher's exact tests.

98 HCV infection and HLA zygosity with 1-sided Fisher's exact tests.

99 aluation included Pearson chi-square and the Fisher's exact tests.

100 nction was compared using Kruskal-Wallis and Fisher's exact tests.

101 Frequencies were compared using chi(2) or Fisher's exact tests.

102 those without affected male relatives, using Fisher's exact tests.

103 lications was performed using chi-square and Fisher's exact tests.

104 es were evaluated using 2-sample t -tests or Fisher's Exact tests.

105 s were compared by use of Mann-Whitney U and Fisher's exact tests.

106 haracteristics were examined with chi(2) and Fisher's exact tests.

107 eived recommended care was compared by using Fisher's exact tests.

108 ites were compared by race and by sex, using Fisher's exact tests.

109 linear regression, 2-sample t, log-rank, and Fisher's exact tests.

110 ithout PTLD (specificity = 100%) (P < 0.001 [Fisher's exact test]).

111 the distribution of subtypes was not random (Fisher's exact test 0.13; P>.05).

112 superior effect of SHUTi versus HealthWatch (Fisher's exact test=0.52; p=0.32).

113 (P = .0002 for comparison to ILV 20 Gy < 3%, Fisher's exact test); 20% (four of 20) for an ILV 10 Gy

114 was significantly associated with c.8057G>A (Fisher's exact test, adjusted p value < 0.0001).

115 stasis) was significantly increased (P=0.04, Fisher's exact test), although there was no increase in

116 Chi-square and Fisher's exact test analysis compared vaccination and do

117 Fisher's Exact Test and a logistic regression model were

118 The chi2 or Fisher's Exact test and ANOVA with adjusted multiple com

119 For statistic analyses Mann-Whitney U-test, Fisher's exact test and binary logistic regression were

120 al rate-comparison methods, e.g. chi 2 test, Fisher's exact test and Binomial test.

121 l characteristics and perceived burden using Fisher's exact test and bivariate modified Poisson regre

122 were analyzed using contingency tables with Fisher's exact test and compared with mismatched antigen

123 isms (with P values obtained with the use of Fisher's exact test and logistic regression ranging from

124 In addition, Fisher's exact test and logistic regression were used to

125 The new approach is compared with Fisher's exact test and other relevant methods in a simu

126 Results were analyzed using Fisher's exact test and Pearson's chi-square test.

127 o commonly used gene set enrichment methods, Fisher's exact test and the binomial test implemented in

128 Patient variables were compared by Fisher's exact test and the Student's t test.

129 Fisher's exact test and Wilcoxon rank sum test were used

130 ps between both arms were compared using the Fisher's exact test and Wilcoxon Rank Sum test.

131 e donors (13/32 vs. 6/41 responders; P=.016, Fisher's exact test) and fewer HLA-DQB1*0603-9/14-positi

132 ted with an increase in tumor size (P=0.009, Fisher's exact test) and lymph node involvement (P=0.04)

133 -, second-, and third-line treatment (chi(2)/Fisher's exact test) and median OS (Kaplan-Meier method/

134 Bivariate (chi-square tests or the Fisher's exact test) and multivariate (logistic regressi

135 ha and ER beta were node positive (P = 0.02; Fisher's exact test) and tended to be of higher grade.

136 tistically superior to the EIA (P, <0.001 by Fisher's exact test) and to the GDH-EIA-CCCN algorithm (

137 versus GAS-positive RA patients [n = 0], by Fisher's exact test), and 2 were also positive for GBS.

138 tein-derivative-negative (PPD-) (P < 0.0001, Fisher's exact test), and 7/8 PPD-positive (PPD+) subjec

139 okers without a history of cancer (P = 0.04, Fisher's exact test), and methylation of DAPK was detect

140 01, P < 0.0001, and P = 0.004, respectively, Fisher's exact test), and the sensitivity of GDH algorit

141 the tamoxifen-sensitive group (P = 0.001 by Fisher's exact test), and, consistent with previous find

142 to approaches such as Pearson's chi square, Fisher's exact test, and a test based on Cressie and Rea

143 Chi-square analysis, Fisher's exact test, and multivariable logistic regressi

144 analyzed by using the chi-square test or the Fisher's exact test, and p < .05 was considered signific

145 sociated with the trait, were identified via Fisher's exact test, and then the ratio of the sSNPs to

146 Fisher's exact tests, and multivariable logistic regress

147 = 0.002 by the chi-square test; P = 0.006 by Fisher's exact test; and after adjustment for relatednes

148 henotype categories of susceptibility, using Fisher's exact test applied to 6,128 markers in publical

149 l probability with the tail probability from Fisher's exact test applied to the actual haplotype data

150 mosomal sites 8p, 9p, 11q, and 13q (P >0.05, Fisher's exact test) are targeted at the early stages, w

151 d -negative groups by Mann-Whitney U test or Fisher's exact test, as appropriate.

152 re compared via Wilcoxon's rank-sum test and Fisher's exact test, as well as multivariate analysis.

153 s versus 0 of 16 control patients (P< .0001, Fisher's exact test) at a median of 32 weeks (range, 17-

154 expected by simple addition alone (P <0.05, Fisher's exact test) between cotinine (800 ng/ml) and 1)

155 l, we adjusted the null distribution for the Fisher's exact test by weighting the identification prob

156 Data analysis included Fisher's exact test, chi-square test, Student's t-test,

157 y significant associations, we performed (a) Fisher's exact test comparing genotypes at each locus in

158 Cotinine significantly (P <0.05, Fisher's exact test) enhanced the effects of cell-free e

159 Fisher's exact test examined the effect of diagnosis on

160 e these methods with each other and with the Fisher's exact test (FET) method.

161 rs within these intervals that display small Fisher's exact test (FET) probabilities is directly prop

162 ) leukemias carried the CYP3A4-V (P = 0.026; Fisher's Exact Test, FET).

163 g a Mann-Whitney test for numerical data and Fisher's exact test for categorical data.

164 Using Fisher's exact test for comparing the numbers of cases a

165 d freedom from were used for analysis as was Fisher's exact test for comparisons between groups.

166 ests, we provide the first implementation of Fisher's exact test for the genotypic cytonuclear disequ

167 ortion of 22q11.2 deletions found, using the Fisher's exact test for the independent case-control stu

168 ssment by each modality using chi-square and Fisher's Exact tests for univariable correlation and log

169 ng-spawner and Norwegian fjord stocks, using Fisher's exact test, FST and RST values.

170 dhood eczema (chi2 test: P = 2.12 x 10(-51); Fisher's exact test: heterozygote odds ratio (OR) = 7.44

171 t week 4 (38% vs. 13%, P=0.04 by a two-sided Fisher's exact test in the A5340 trial; and 80% vs. 13%,

172 ial; and 80% vs. 13%, P<0.001 by a two-sided Fisher's exact test in the NIH trial) but the difference

173 irwise LD was estimated using three methods: Fisher's exact test, index of association (IA) and Hedri

174 Statistical analysis (Fisher's exact test) indicated there was no significant

175 ined analysis (p = 2.68 x 10(-4), two-tailed Fisher's exact test), indicating that the SLC2A3 duplica

176 The Fisher's exact test is commonly used.

177 Fisher's exact test is direct, but not suitable for data

178 he data were analyzed using a combination of Fisher's exact test, logistic regression modeling, and m

179 We analyzed the results using Fisher's exact tests, logistic regression, and generaliz

180 hereas LOH at 1p, 5q, 17p, and 18q (P <0.05, Fisher's exact test) occur at the later stages of non-sm

181 Dichotomous variables were compared by Fisher's exact test; odds ratios were indicated when app

182 ients: MTHF, 2 of 25 (8%); FA, 0 of 25 (0%); Fisher's exact test of between-groups difference, P=0.49

183 Descriptive, Chi-square test, Fisher's exact test, one way ANOVA, and Multinomial logi

184 the C102 allele and the presence of visual (Fisher's exact test, one-tailed, P = 0.003) and auditory

185 led, P = 0.003) and auditory hallucinations (Fisher's exact test, one-tailed, P = 0.004) and between

186 ome and histamine levels were assessed using Fisher's exact test or Student's t-test.

187 lar compartment and prognostic factors using Fisher's Exact test or with patient survival over 20 yea

188 ar groups, respectively (IPV versus control: Fisher's exact test P < 0.001).

189 ngly associated with induction of apoptosis (Fisher's exact test P < 0.015) and reduction in urine ba

190 se groups was not statistically significant (Fisher's exact test P = .4241).

191 es were more likely to be treated with UDCA (Fisher's exact test p = 0.0178) than those with a lower

192 significantly reduced at 1, 12 and 52 weeks (Fisher's Exact Test p = 0.018, chi(2) = 5.1 p = 0.02 and

193 red with single-vision spectacles (one-sided Fisher's exact test P = 0.025).

194 ne of 12 patients with plaque-stage disease (Fisher's exact test p = 0.027).

195 ned significant (OR = 3.69, 95%CI:2.02-6.73, Fisher's exact test P = 1.06E-06).

196 on in idiopathic focal childhood epilepsies (Fisher's exact test P = 2.1 x 10(-4)).

197 rols (5/393 cases versus 32/65,046 controls; Fisher's exact test P = 2.83 x 10(-6), odds ratio = 26.2

198 red to controls (OR = 5.08, 95%CI:2.81-9.20, Fisher's exact test P = 6.30E-11).

199 sis revealed a significant burden for VPS16 (Fisher's exact test p value, 6.9 x 10(9) ).

200 red with secondary groups (11/49 vs 211/230: Fisher's exact test p<0.0001).

201 y of GCH1 variants was significantly higher (Fisher's exact test P-value 0.0001) in cases (10/1318 =

202 mpared with three (9%) of the 32 on placebo (Fisher's exact test p=0.05).

203 locations involving CBFA2 was significant by Fisher's exact test (P < .003).

204 evated PET score (i.e., PET score > 1) using Fisher's exact test (P < 0.05).

205 n all tumor types by both the chi(2) and the Fisher's exact tests (P < 0.0001 for both tests).

206 ases in volunteers receiving active product (Fisher's exact test, P < .0017).

207 with sun-protected sites (1.1%, one of 90) (Fisher's exact test, p < 0.0001).

208 the Fanconi anemia protein FANCD2 (corrected Fisher's exact test, P < 0.0007).

209 ed axillary lymph nodes, a high concordance (Fisher's exact test, P < 0.001) was seen between PCR det

210 cancer as compared with the benign prostate (Fisher's exact test, P < 0.001).

211 form aneurysms (and 0/38 saccular aneurysms; Fisher's exact test, p < 0.001).

212 compared with nonresponders (11 of 20, 55%; Fisher's exact test, P < 0.029).

213 were 9.9% for FOLFOX4 versus 0% for LV5FU2 (Fisher's exact test, P <.0001).

214 h women more likely to be affected than men (Fisher's exact test, P = .0197).

215 genetic distance (GD) <1.5% than in the GP (Fisher's exact test, p = 0.001).

216 ociated with protection against reinfection (Fisher's exact test, P = 0.002).

217 common c.2439C/C (89% vs 40%, respectively; Fisher's exact test, P = 0.01).

218 nce in wild-type littermates (16 of 19; 84%; Fisher's exact test, P = 0.012).

219 st to 0.6% (2 of 327) in 327 unaffected men (Fisher's exact test, P = 0.018), with an odds ratio (OR)

220 eased in FTAAD compared with STAAD patients (Fisher's exact test, p = 0.03).

221 ithout sporadic medullary thyroid carcinoma (Fisher's exact test, P = 0.03).

222 gated across affected and unaffected groups (Fisher's exact test, P = 0.034).

223 ong patients with type II diabetes mellitus (Fisher's exact test, p = 0.035).

224 mary tumors without distant metastasis (5%) (Fisher's exact test, P = 0.05; chi(2) = 0.04).

225 d to gnomAD v.4.0 population-based controls (Fisher's exact test, p = 1.44 x 10-5).

226 ost somatic HPV16 APOBEC3-induced mutations (Fisher's exact test, P = 6.2 x 10(-14)), and have a 30%

227 ard reduction in the incidence of infection (Fisher's exact test, p =.07; odds ratio,.76) in the gown

228 s, in which aneuploidy was more common (69%; Fisher's exact test, P=0.0033).

229 nt compared with 38% in the wait-list group (Fisher's exact test, P=0.01).

230 id not correlate with absent pRB expression (Fisher's exact test, P=0.375).

231 interview modes (12.5% ACASI vs. 10.9% FTFI; Fisher's exact test: P = 0.72).

232 operfusion of right superior temporal gyrus (Fisher's exact test; p < 0.0001), whereas left "egocentr

233 g > Rev > Pol > Nef > Vif > Tat > Env > Vpu (Fisher's exact test; P < or = 0.0009 for each comparison

234 LA-DQB1*0301-negative patients (52% vs. 88%; Fisher's Exact Test; P = 0.007).

235 bination with pmurGMCSF gave 40% protection (Fisher's exact test; P = 0.03, vaccinated versus control

236 n and HPV infection were mutually exclusive (Fisher's exact test; P = 0.0357): two HPV-negative cervi

237 n (64 of 67 ears with elevated protein; 96%)(Fisher's exact test; P<0.0001) in both normal and hearin

238 hearing loss (32/34 hearing loss ears; 94%)(Fisher's exact test; P= .005).

239 sic descriptive statistics, chi-square test, Fisher's exact test, Pearson correlation and Poisson reg

240 gnosis), we found a significant (P < 0.0001, Fisher's exact test) reduction in the number of edematou

241 pite a serious limitation, a method based on Fisher's exact test remains one of the few plausible opt

242 ns were made by using two sample t tests and Fisher's exact tests, respectively.

243 onse and improvement in QoL were assessed by Fisher's exact test statistic.

244 In the Bloom syndrome trial, by Fisher's exact test, statistically significant associati

245 sing different statistical methods including Fisher's Exact Test, Student's t-test, ANOVA, non-parame

246 urg, Germany) was significantly (P = 0.0096, Fisher's exact test) superior to orally administered dru

247 orrelation T(IC), as well as to the power of Fisher's exact test T(FET) applied to discretized data.

248 among the groups using Pearson's chi2 test, Fisher's exact test, t-test and ANOVA.

249 ed an increased prevalence of Apa1 A (P=.03; Fisher's exact test), TaqI t (P=.04), and the At VDR hap

250 DPRP provides three methods: the Fisher's Exact Test, the Kolmogorov-Smirnov test and the

251 ple uses on bisulfite-seq with P-values from Fisher's exact test, tiled methylation probes using a li

252 We used Fisher's exact test to compare unadjusted attack rates a

253 acid or N-glycosylation motif, and performs Fisher's exact test to detect potential positive or nega

254 By applying Fisher's exact test to identify enriched KEGG pathways a

255 l form, can be viewed as a generalization of Fisher's exact test to ternary variables.

256 iled Mann Whitney U exact tests, chi(2), and Fisher's exact tests to analyse the data.

257 We used t tests, chi(2) tests, and Fisher's exact tests to compare baseline demographics ac

258 We used chi(2) and Fisher's exact tests to compare categorical variables an

259 We performed chi-square and Fisher's exact tests to compare the frequencies of obser

260 alysis of variance for change from baseline, Fisher's exact test (two-tailed) for categorical compari

261 ive for enterovirus D68 using the two-tailed Fisher's exact test, two-sample unpaired t test, and Man

262 contrasted with absence of disease (P=0.029, Fisher's exact test, two-sided, verified by permutation

263 hi-square testing for categorical variables (Fisher's exact test used for violations of Cochran's ass

264 mpared using ANOVA, Pearson's chi-square, or Fisher's exact tests using R software.

265 One-tail Fisher's exact test was conducted on each cross validati

266 Fisher's exact test was done for each single-nucleotide

267 n was declared if the one-sided p value with Fisher's exact test was less than 0.2.

268 tudent's t-test analyses were performed, and Fisher's exact test was used as appropriate.

269 Fisher's exact test was used for categoric variables, an

270 Fisher's exact test was used for comparisons.

271 Fisher's exact test was used for the primary end point,

272 Fisher's exact test was used to compare differences betw

273 Fisher's exact test was used to compare incidence and se

274 The Fisher's exact test was used to compare patient groups.

275 -test was used to compare average values and Fisher's exact test was used to compare proportions.

276 Fisher's exact test was used to compare the proportion o

277 Fisher's exact test was used to detect differences betwe

278 Fisher's exact test was used to determine difference in

279 Fisher's exact test was used to screen for association w

280 Although no statistical difference (Fisher's exact test) was detected (P = 0.242) between th

281 and Neisseria lactamica (P < 0.002) (2-sided Fisher's exact test) was more likely in the smaller, mor

282 ANOVA and Fisher's exact test were conducted to examine the differ

283 Kaplan-Meier analysis and Fisher's exact test were used for comparisons between gr

284 Descriptive statistics, chi-square test and Fisher's exact test were used for data analysis with sta

285 ), Bland-Altman plot, kappa statistics, and Fisher's exact test were used to assess intra- and inter

286 Chi square and Fisher's exact test were used to evaluate differences be

287 Descriptive statistics and Fisher's exact tests were used to assess associations, w

288 Cross-tabulations, chi-squared tests, and Fisher's exact tests were used to assess the influences

289 Chi-square tests and Fisher's exact tests were used to compare the demographi

290 used for continuous variables and t-tests or Fisher's exact tests were used to compare treatment grou

291 Fisher's exact tests were used to compare, by frailty st

292 ive and comparative analyses (chi-square and Fisher's exact test) were performed of national estimate

293 Pearson chi square analysis or Fisher's exact test, when appropriate, was used for univ

294 c effects on longevity were also analyzed by Fisher's exact test, which indicated a significant life-

295 h HTS (31.3%) and none with ETS (P = 0.0135, Fisher's exact test), while an aura with experiential co

296 tected, pairwise comparisons were made using Fisher's exact test with a Bonferroni adjustment.

297 henotypes and CISs are also identified using Fisher's exact test with multiple testing correction.

298 in vivo is strongly associated (P < 2e-16 by Fisher's exact test) with nucleosome-free chromatin.

299 Fisher's exact test, with correction for multiple compar

300 ignificance was determined by chi-square and Fisher's exact tests, with a false discovery rate correc